Alzheimer's Disease (AD) Progression and Healthcare Resource Utilization (HRU) in Preclinical AD
As AD progresses from preclinical to early symptomatic, Medicare spending increases. These results highlight the need for additional research on cost savings associated with delaying progression to symptomatic stages of disease.
Authors
- Karen C. Holdridge
- M S Rafii
- Angelina Lee
- Nalin Payakachat (ORCID: https://orcid.org/0000-0002-9526-5356)
- Julie Chandler
- Zachary T. Sheff (ORCID: https://orcid.org/0000-0002-1126-5712)
- Joanna Kubisiak
- Roy Yaari
- Paul S. Aisen
- Reisa A. Sperling
Institutions
- University of Southern California (US)
- Brigham and Women's Hospital (US)
- Autism Research Institute (US)
- Westat (United States) (US)
- Harvard University (US)
- Eli Lilly (United States) (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70860_103138
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00